New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

June 2014

Palatin Technologies to Join Russell Microcap Index

Press Releases / By

CRANBURY, N.J., June 27, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes …

Palatin Technologies to Join Russell Microcap Index Read More »

Palatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin Receptor-Specific Peptides

Press Releases / By

CRANBURY, N.J., June 10, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application …

Palatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin Receptor-Specific Peptides Read More »

Scroll to Top